$CHMX
NEXT-ChemX Corporation.

2023 Q2 Form 10-Q Financial Statement

#000149315223017377 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $500.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $581.6K $436.7K $374.1K
YoY Change 32.69% 16.72% 2146.91%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.340K $1.330K $1.200K
YoY Change 3.88% 10.83%
% of Gross Profit
Operating Expenses $581.6K $436.7K $374.1K
YoY Change 32.69% 16.72% 2146.91%
Operating Profit -$581.6K -$436.7K -$374.1K
YoY Change 32.69% 16.72%
Interest Expense $19.20K $21.32K -$13.78K
YoY Change -218.38% -254.72%
% of Operating Profit
Other Income/Expense, Net $183.8K -$21.32K -$13.78K
YoY Change -1233.19% 54.71%
Pretax Income -$397.7K -$458.0K -$387.9K
YoY Change -12.5% 18.07% 2229.67%
Income Tax
% Of Pretax Income
Net Earnings -$397.7K -$458.0K -$387.9K
YoY Change -12.5% 18.07% 2229.67%
Net Earnings / Revenue -79.54%
Basic Earnings Per Share -$0.01 -$0.02 -$0.01
Diluted Earnings Per Share -$0.01 -$0.02 -$14.16K
COMMON SHARES
Basic Shares Outstanding 28.45M shares 28.85M shares 27.39M shares
Diluted Shares Outstanding 28.45M shares 28.37M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.2K $142.2K $17.99K
YoY Change 202.95% 690.44% 8.11%
Cash & Equivalents $57.68K $142.2K $17.99K
Short-Term Investments $101.5K
Other Short-Term Assets $73.25K $13.33K $1.600K
YoY Change 4478.13% 733.13% 25.98%
Inventory
Prepaid Expenses $1.600K
Receivables
Other Receivables
Total Short-Term Assets $232.5K $155.5K $19.59K
YoY Change 329.25% 693.94% 9.38%
LONG-TERM ASSETS
Property, Plant & Equipment $15.29K $16.62K $20.34K
YoY Change -25.87% -18.27%
Goodwill
YoY Change
Intangibles $3.150M $3.150M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.165M $3.167M $3.170M
YoY Change -0.17% -0.12%
TOTAL ASSETS
Total Short-Term Assets $232.5K $155.5K $19.59K
Total Long-Term Assets $3.165M $3.167M $3.170M
Total Assets $3.398M $3.322M $3.190M
YoY Change 5.36% 4.15% 17711.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $525.6K $529.6K $435.7K
YoY Change -5.65% 21.54% 1143.55%
Accrued Expenses $1.342M $1.150M $618.1K
YoY Change 86.28% 86.0%
Deferred Revenue
YoY Change
Short-Term Debt $641.9K $857.2K $124.1K
YoY Change 111.91% 590.61% 107.21%
Long-Term Debt Due $687.5K
YoY Change
Total Short-Term Liabilities $3.022M $2.548M $1.865M
YoY Change 55.52% 36.61% 887.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.022M $2.548M $1.865M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.022M $2.548M $1.865M
YoY Change 55.52% 36.61% 887.16%
SHAREHOLDERS EQUITY
Retained Earnings -$4.548M -$4.151M
YoY Change 62.95%
Common Stock $28.45K $28.45K
YoY Change 1.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $376.2K $773.9K $1.325M
YoY Change
Total Liabilities & Shareholders Equity $3.398M $3.322M $3.190M
YoY Change 5.36% 4.15% 17711.5%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$397.7K -$458.0K -$387.9K
YoY Change -12.5% 18.07% 2229.67%
Depreciation, Depletion And Amortization $1.340K $1.330K $1.200K
YoY Change 3.88% 10.83%
Cash From Operating Activities $140.5K -$310.1K -$110.7K
YoY Change -169.32% 180.27% 295.5%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -225.0K $424.0K 118.2K
YoY Change -194.23% 258.65%
NET CHANGE
Cash From Operating Activities 140.5K -$310.1K -110.7K
Cash From Investing Activities 0.000
Cash From Financing Activities -225.0K $424.0K 118.2K
Net Change In Cash -84.52K $113.8K $0.00
YoY Change -344.56%
FREE CASH FLOW
Cash From Operating Activities $140.5K -$310.1K -$110.7K
Capital Expenditures $0.00
Free Cash Flow $140.5K -$310.1K -$110.7K
YoY Change -169.87% 180.27% 295.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001657045
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 CHMX Due To Other Related Parties Current
DueToOtherRelatedPartiesCurrent
usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q1 CHMX Proceeds From Stock Issuance Of Common Stocks
ProceedsFromStockIssuanceOfCommonStocks
usd
CY2022Q1 CHMX Proceeds From Notes Payable Third Party
ProceedsFromNotesPayableThirdParty
usd
CY2022Q1 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 CHMX Accrued Interest Related Party
AccruedInterestRelatedParty
usd
CY2022Q4 CHMX Accrued Interest Related Party
AccruedInterestRelatedParty
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-56379
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
NEXT-ChemX Corporation
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0446353
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
901 Mopac Expressway South
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building 1
CY2023Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 300
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
CY2023Q1 dei City Area Code
CityAreaCode
(512)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
663-2690
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28446834 shares
CY2023Q1 us-gaap Cash
Cash
142203 usd
CY2022Q4 us-gaap Cash
Cash
28355 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13330 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22169 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
155533 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
50524 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16623 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17957 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3150114 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3150114 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
3166737 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3168071 usd
CY2023Q1 us-gaap Assets
Assets
3322270 usd
CY2022Q4 us-gaap Assets
Assets
3218595 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1679203 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1548740 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
11980 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
11980 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
850000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
926007 usd
CY2023Q1 CHMX Due To Other Related Parties Current
DueToOtherRelatedPartiesCurrent
7192 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2548375 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2486727 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2548375 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2486727 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28446834 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28446834 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28346834 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28346834 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
28447 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
28347 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4896153 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4396253 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4150705 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3692732 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
773895 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
731868 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3322270 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3218595 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
436653 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
374109 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
436653 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
374109 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-436653 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-374109 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
21320 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
13781 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21320 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13781 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-457973 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-387890 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28374612 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27385437 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
731868 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-457973 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
773895 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1712486 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-387890 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1324596 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-457973 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-387890 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1334 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1202 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-8839 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
137655 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
276027 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-310145 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-110661 usd
CY2023Q1 CHMX Proceeds From Stock Issuance Of Common Stocks
ProceedsFromStockIssuanceOfCommonStocks
500000 usd
CY2023Q1 CHMX Proceeds From Notes Payable Third Party
ProceedsFromNotesPayableThirdParty
75000 usd
CY2023Q1 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-151007 usd
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
118220 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
423993 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
118220 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
113848 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7559 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28355 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10429 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142203 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17988 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4150705 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-457973 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-387890 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-310145 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-110661 usd
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
308161 usd
CY2023Q1 us-gaap Notes Payable
NotesPayable
297000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
776638 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_z4BtZkqtz7F5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zs9b7N9x88ra">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3150114 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13330 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22169 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-8839 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1600 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3150114 usd
CY2023Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
529580 usd
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
471567 usd
CY2023Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1114402 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1051192 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
35221 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
25981 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1679203 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1548740 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
426006.86 usd
CY2022 us-gaap Debt Instrument Redemption Price Percentage
DebtInstrumentRedemptionPricePercentage
0.08 pure
CY2023Q1 us-gaap Loans Payable
LoansPayable
151007 usd
CY2023Q1 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
275000 usd
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2022Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10 pure
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
75000 usd
CY2023Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10 pure
CY2023Q1 us-gaap Interest Expense
InterestExpense
21320 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28446834 shares
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
100000 shares

Files In Submission

Name View Source Status
chmx-20230331_cal.xml Edgar Link unprocessable
chmx-20230331_def.xml Edgar Link unprocessable
0001493152-23-017377-index-headers.html Edgar Link pending
0001493152-23-017377-index.html Edgar Link pending
0001493152-23-017377.txt Edgar Link pending
0001493152-23-017377-xbrl.zip Edgar Link pending
chmx-20230331.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
chmx-20230331_lab.xml Edgar Link unprocessable
chmx-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed